Legislative proposals to amend the exclusion have been introduced in Congress (the Treat and Reduce Obesity Act, reintroduced in 2025) but have not passed as of April 2026
These side effects can then lead to dehydration and nutrient deficiencies, which, in turn, may pave the way for other issues like hair loss or fatigue
What does the FDA's April 30, 2026 announcement mean for someone currently on or starting a compounded GLP-1 program
Store the vial in a cool, dry place, protected from light
You can choose to pick up your medication at the clinic or have it shipped directly to your doorstep
NICE guidance recommends considering GLP-1 receptor agonists (including dual agonists like tirzepatide) for type 2 diabetes when additional glycaemic control is needed, particularly in those who would benefit from weight loss